Lartruvo▼ (olaratumab): withdrawal of the EU marketing authorisation due to lack of efficacy

2019-06-19T14:14:06+01:00

The ANNOUNCE study failed to show clinical efficacy for olaratumab in its current indication of advanced soft tissue sarcoma and the benefit risk balance is therefore now considered negative. No new patients should be started on olaratumab therapy.…